Literature DB >> 22302265

Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures.

Russell N Low1, Robert M Barone.   

Abstract

PURPOSE: To determine whether abdominal and pelvic magnetic resonance imaging (MRI) with diffusion-weighted and dynamic gadolinium-enhanced imaging can be used to accurately calculate the peritoneal cancer index (PCI) before surgery compared to the PCI tabulated at surgery.
METHODS: Thirty-three patients underwent preoperative MRI followed by cytoreductive surgery for primary tumors of the appendix (n = 25), ovary (n = 5), colon (n = 2), and mesothelioma (n = 1). MRIs were retrospectively reviewed to determine the MRI PCI. These scores were then compared to PCI tabulated at surgery. Patients were categorized as having small-volume tumors (PCI 0–9), moderate-volume tumors (PCI 10–20), and large-volume tumors (PCI > 20). The respective anatomic site scores for both MRI and surgery were compared.
RESULTS: There was no significant difference between the MRI PCI and surgical PCI for the 33 patients (P = 0.12). MRI correctly predicted the PCI category in 29 (0.88) of 33 patients. Compared to surgical findings, MRI correctly predicted small-volume tumor in 6 of 7 patients, moderate-volume tumor in 3 of 4 patients, and large-volume tumor in 20 of 22 patients. MRI and surgical PCI scores were identical in 8 patients (24%). A difference of <5 was noted in 16 patients (49%) and of 5–10 in 9 patients (27%). Compared to surgical-site findings, MRI depicted 258 truly positive sites of peritoneal tumor, 35 falsely negative sites, 35 falsely positive sites, and 101 truly negative sites, with a corresponding sensitivity of 0.88, specificity of 0.74, and accuracy of 0.84.
CONCLUSIONS: Combined diffusion-weighted and gadolinium-enhanced peritoneal MRI accurately predicts the PCI before surgery in patients undergoing evaluation for cytoreductive surgery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302265     DOI: 10.1245/s10434-012-2236-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  30 in total

Review 1.  Malignant peritoneal mesothelioma: a review.

Authors:  Joseph Kim; Shanel Bhagwandin; Daniel M Labow
Journal:  Ann Transl Med       Date:  2017-06

Review 2.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

Review 3.  Preoperative and surveillance MR imaging of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.

Authors:  Russell N Low
Journal:  J Gastrointest Oncol       Date:  2016-02

Review 4.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

Review 5.  Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients.

Authors:  Lucas Minig; Cristina Zorrero; Pablo Padilla Iserte; Andres Poveda
Journal:  World J Methodol       Date:  2015-12-26

6.  Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.

Authors:  Deepa Magge; Mazen S Zenati; Frances Austin; Arun Mavanur; Magesh Sathaiah; Lekshmi Ramalingam; Heather Jones; Amer H Zureikat; Matthew Holtzman; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-12-10       Impact factor: 5.344

7.  Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.

Authors:  Katrijn Michielsen; Ignace Vergote; Katya Op de Beeck; Frederic Amant; Karin Leunen; Philippe Moerman; Christophe Deroose; Geert Souverijns; Steven Dymarkowski; Frederik De Keyzer; Vincent Vandecaveye
Journal:  Eur Radiol       Date:  2013-12-11       Impact factor: 5.315

Review 8.  Malignant peritoneal mesothelioma: a review.

Authors:  Glenn Broeckx; Patrick Pauwels
Journal:  Transl Lung Cancer Res       Date:  2018-10

9.  FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.

Authors:  E Bonnet; C Mastier; A Lardy-Cléaud; P Rochefort; M Sarabi; P Guibert; A Cattey-Javouhey; F Desseigne; C de La Fouchardière
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

10.  Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma.

Authors:  Mercedes Espada; Jose R Garcia-Flores; Mar Jimenez; Elena Alvarez-Moreno; Mar De Haro; Lucia Gonzalez-Cortijo; Gines Hernandez-Cortes; Vicente Martinez-Vega; Ricardo Sainz De La Cuesta
Journal:  Eur Radiol       Date:  2013-04-19       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.